SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently trending as investors anticipate long-term Week 40 clinical data for their flagship candidate, sonelokimab, which is set to be presented at an upcoming dermatology conference. The community is heavily focused on the drug's potential to establish a 'best-in-class' profile for treating Hidradenitis Suppurativa, with active discussions revolving around institutional accumulation patterns, recent analyst upgrades, and persistent speculation regarding potential M&A interest from major pharmaceutical players.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is currently capturing significant community attention following its mainnet rollout and integrations with major financial institutions like MoneyGram and Monument Bank, which aim to drive regulated, privacy-focused adoption. While some investors remain cautious due to the heavy influence of Google Cloud in its infrastructure and lingering skepticism from some Cardano community members regarding Charles Hoskinsons leadership, bullish participants are actively discussing the potential of its zero-knowledge technology and upcoming airdrops to catalyze long-term growth.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is currently under downward pressure following a disappointing quarterly earnings report where the company missed profit estimates and lowered its full-year guidance due to weak consumer demand and a stagnant housing market. Community sentiment is deeply divided; while some investors view the current dip as a long-term value opportunity for a sector leader, many traders are actively shorting the stock, citing ongoing macro headwinds, concerns over high-ticket renovation project delays, and a pessimistic outlook for the broader housing sector.

Borr Drilling Ltd. engages in the provision of offshore drilling services to the oil and gas industry. It operates through Dayrate; and Integrated Well Services (IWS) segments. The Dayrate segment consists of rig charters and ancillary services. The IWS segment provides integrated well services through Opex and Akal. The company was founded by Tor Olav Trøim on August 8, 2016 and is headquartered in Hamilton, Bermuda.

Borr Drilling Ltd

Borr Drilling is capturing market attention as investors weigh the impact of recent contract expansions and a transition in executive leadership against persistent debt concerns. The community remains divided, with many traders actively accumulating shares based on potential upside in the offshore rig market, while others express caution regarding the company's long-term financial leverage.

iShares Trust - iShares MSCI India ETF

iShares MSCI India ETF

The iShares MSCI India ETF (INDA) is currently in focus as investors weigh the potential impact of looming U.S. reciprocal tariffs and geopolitical tensions against the nation's robust long-term growth story and ongoing trade deal negotiations. While market participants are actively discussing the risks of foreign equity outflows and currency volatility, many community members remain bullish on India's resilience and its strategic potential as a global manufacturing hub.

BlockDAG is a hybrid concept that combines features of both traditional blockchains and DAGs. It retains the benefits of DAGs, such as high scalability and faster transaction processing, while integrating the security and trust of blockchain consensus mechanisms. BlockDAG emerges as a groundbreaking solution, meticulously merging the strengths of both blockchain and DAG architectures. It leverages the robust security and decentralization of blockchains while incorporating the efficient, scalable transaction processing of DAGs. This strategic integration allows blockDAG to handle a significantly higher volume of transactions at faster speeds compared to traditional blockchains. By overcoming the inherent limitations of both technologies, blockDAG paves the way for a future where distributed ledgers can seamlessly scale to meet the ever-growing demands of the cryptocurrency and broader digital landscape.

BlockDAG

BlockDAG is currently trending due to intense community frustration surrounding difficulties with token claims, confusing wallet connectivity, and widespread accusations that the project operates as a scam. While some proponents continue to push the mining app and long-term potential, many investors are actively sharing warnings and seeking legal recourse due to the lack of clear, functional access to their holdings.

Halliburton Co. engages in the provision of products and services to the energy industry. It operates through the Completion and Production, and Drilling and Evaluation segments. The Completion and Production segment focuses on cementing, stimulation, specialty chemicals, intervention, pressure control, artificial lift, and completion products and services. The Drilling and Evaluation segment provides field and reservoir modeling, drilling, fluids, evaluation, and wellbore placement solutions that enable customers to model, measure, drill, and optimize well construction activities. The company was founded by Erle P. Halliburton in 1919 and is headquartered in Houston, TX.

Halliburton Co.

Halliburton is trending as the energy sector evaluates the potential impact of major geopolitical shifts in Venezuela, with investors closely watching how integrated service providers could play a role in infrastructure reconstruction. The community is actively discussing the stock's long-term valuation and strategic position, with some traders monitoring unusual options activity while others debate whether the current price point represents a buying opportunity or a warning sign amid broader market rotation into energy.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is currently under significant investor scrutiny as the stock tests multi-year technical support levels amidst broader healthcare policy uncertainty and skepticism regarding its 2026 path to profitability. While some community members view the current depressed price as an asymmetric opportunity based on long-term membership growth and AI-driven efficiency, others remain vocal about fundamental risks related to medical loss ratios and the sustainability of the company's growth narrative.

MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It targets local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet needs. The company was founded on March 20, 2015 and is headquartered in New York, NY.

MeiraGTx Holdings plc

MeiraGTx is gaining significant momentum as investors digest positive phase 2 results for its AAV-GAD Parkinsons disease therapy and anticipation builds around pivotal trial readouts for its gene therapy pipeline. The community is focused on the company's robust strategic partnerships with major pharmaceutical players and the potential for its proprietary Riboswitch gene regulation platform to unlock substantial value across metabolic and CNS therapeutic areas.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF (VTI) is trending amid widespread investor discussion regarding broader market volatility and uncertainty stemming from shifting geopolitical tensions and domestic political discourse. Community members are actively debating the merits of long-term indexing strategies like VTI as a defensive hedge against the potential for continued instability in large-cap tech and traditional sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q1 Earnings Forecast for CAPR Issued By HC Wainwright

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a...

<ul class="summary-bullets"><li>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on Friday's selloff.</li><li>B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares.</li><li>The Food and Drug Administration has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22.</li></ul>Shares of Capricor Therapeutics (CAPR) fell 9% on Friday after the company reported a wider-than-expected Q4 loss but Wall Street analysts raised their price targets on the stock over hopes for an approval of the company’s lead candidate.On the company’s fourth-quarter (Q4) <a href="https://stocktwits.com/news-articles/markets/equity/capricor-reports-wider-quaterly-loss-than-expected-but-all-eyes-are-on-deramiocel/cZduNXsRIad">earnings</a> call, CEO Linda Marban <a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-best-week-month-ceo-rules-out-conditional-deramiocel-approval/cZdDdk4RIa1">rejected</a> the possibility that the Deramiocel therapy could receive only a conditional regulatory decision. The U.S. Food and Drug Administration is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">Wall Street Take Aways</h2>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on today's selloff. The 8% pullback is a "transient, healthy and short-lived market correction" following the rally post FDA acceptance of Capricor's application of Deramiocel for the treatment of Duchenne muscular dystrophy, the analyst told investors in a research note. Roth would be buying today's "dislocation" and expects the share price to move towards its price target of $41. The firm has a ‘Buy’ rating on Capricor.B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares. The analyst said that its confidence has increased in a potential smooth approval path for Deramiocel ahead of the August 22 decision date, with shares expected to build into the decision as investors digest additional dataset, the analyst told investors in a research note.Piper Sandler raised the firm's price target on CAPR to $58 from $45 and kept an ‘Overweight’ rating on the shares. The firm noted Capricor ended 2025 with cash of $318 million to fund operations through 2027. The FDA has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22. Optimistically, the label could include the broad Duchenne muscular dystrophy population, not just DMD cardiomyopathy, Piper argues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained 138% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-will-delay-release-of-cybercab-until-late-2026-owing-to-safety-issues-fund-manager-predicts/cZdDVgaRIO9">Tesla Will Delay The Release Of Cybercab Until Late-2026 Owing To Safety Issues, Fund Manager Predicts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval

On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval.

Equity

B. Riley Financial Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price

B. Riley Financial raised their price target on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the stock a "buy" rating in a report on Friday...

Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates

Capricor Therapeutics shares are trading lower Friday afternoon after the biotech company reported a wider-than-expected fourth-quarter loss.read more...

Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.3% - Time to Sell?

Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6.3% - Should You Sell...

Capricor Therapeutics (NASDAQ:CAPR) Given Overweight Rating at Piper Sandler

Piper Sandler reaffirmed an "overweight" rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday...

Pier Capital LLC Boosts Stock Position in Capricor Therapeutics, Inc. $CAPR

Pier Capital LLC increased its holdings in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 35.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund...

<ul class="summary-bullets"><li>CEO Linda Marban dismissed concerns that Deramiocel would receive a conditional approval, citing a trial that met both primary and key secondary endpoints.</li><li>The company is preparing for a potential launch, with its San Diego manufacturing capable of initially treating about 250 patients per year.</li><li>Capricor reported a wider-than-expected Q4 loss of $0.62 per share and no revenue, but ended 2025 with about $318.1 million in cash.</li></ul>Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban has pushed back on regulatory doubts around its Duchenne Muscular Dystrophy (DMD) therapy Deramiocel, saying there is “no way” the drug ends up with only a conditional FDA approval, providing some<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is heading for its best week since Feb. 20.<h2 class="st-heading-2">CEO Rejects Conditional Approval Risk For Deramiocel</h2>On the company’s fourth-quarter (Q4) earnings call, CEO Linda Marban rejected the possibility that the therapy could receive only a conditional regulatory decision. “No. There’s no way this would be a conditional approval,” Marban said, noting that the trial supporting the application was a randomized, double-blind, placebo-controlled study that met its primary endpoint as well as key secondary endpoints.The comments came after the U.S. Food and Drug Administration (FDA) accepted Capricor’s&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-dmd-therapy-phase3-heart-function-results/cZdu4NvRI9m">resubmitted</a> biologics license application for Deramiocel, setting a PDUFA decision date of Aug. 22.&nbsp;Capricor is seeking full approval of Deramiocel for Duchenne muscular dystrophy (DMD) and expects the data to support labeling that reflects benefits in both skeletal muscle and heart disease associated with the condition.<h2 class="st-heading-2">Launch Preparations Underway</h2>The company is also preparing for commercialization if the therapy wins regulatory clearance. Capricor’s San Diego GMP manufacturing facility has already completed its FDA pre-license inspection and is positioned to support an initial commercial launch. The site currently has&nbsp;the capacity to treat about 250 patients per year.Marban said the company plans to begin stockpiling commercial doses once labeling discussions with the FDA are finalized, signaling confidence in the potential approval.Capricor is also expanding manufacturing capacity with additional clean rooms at the same facility, which the company expects could increase production to roughly 2,500 patients per year once fully operational.<h2 class="st-heading-2">Clinical Data Supporting Approval</h2>Deramiocel’s application is supported by results from the Phase 3 Hope-3 trial, which met its primary endpoint measuring upper-limb function and key cardiac endpoints in patients with Duchenne muscular dystrophy. Additional data presented&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-dmd-therapy-phase3-heart-function-results/cZdu4NvRI9m">this week</a> showed reduced cardiac fibrosis and improvements in functional measures tied to daily activities.Marban said physician sentiment around the therapy has strengthened following the new data. “Physicians who before were hopeful are now convinced,” she said, adding that the company is receiving increasing inquiries about prescribing and availability.<h2 class="st-heading-2">CAPR Q4 Review</h2>Capricor reported a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-dmd-therapy-phase3-heart-function-results/cZdu4NvRI9m">Q4 loss</a> of $0.62 per share, wider than analysts’ estimate of a $0.55 loss per share. The company reported nil revenue, compared with about $11.1 million a year ago, as milestone payments tied to its partnership with Nippon Shinyaku had already been fully recognized.The company ended 2025 with about $318.1 million in cash, which will fund operations into late 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CAPR was ‘extremely bullish’ amid over a 700% surge in message volumes over the past month.<figure class="image"><img src="https://news.stocktwits-cdn.com/capr_ss_png_4b733f342d.webp" alt="capr ss.png" width="971" height="145"><figcaption>CAPR sentiment and message volume as of March 13 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/RaymondBabbitt/message/647418188">said</a>, “Congratulations to the Bulls, and to the patients who have been waiting for a miraculous discovery to treat their illness of DMD - Deramiocel, is just around the corner.”<stembedurl>https://stocktwits.com/RaymondBabbitt/message/647418188</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Bentradez/message/647424625">said</a> interest in Deramiocel was strong, noting that participants are expected to join quickly and that others have been reaching out to try to take part, adding that “the demand is there for sure.”<stembedurl>https://stocktwits.com/Bentradez/message/647424625</stembedurl>The stock has surged over 150% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval

The FDA has accepted Capricor’s resubmitted biologics license application, setting an Aug. 22 PDUFA decision date for Deramiocel in DMD. 

<ul><li>The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million.</li><li>Capricor is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22.</li><li>The FDA reversed course on its previous rejection for Deramiocel earlier this week.</li></ul>&nbsp;Shares of Capricor Therapeutics (CAPR) slid down about 2% after-hours on Thursday, after the company reported wider-than-expected quarterly loss, partially offset by optimism for the company’s pipeline.For the fourth quarter, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/340/capricor-therapeutics-reports-fourth-quarter-and-full-year">reported</a> a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024, and more than a Wall Street estimate of a loss of $0.54.The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million. The company now believes this to be sufficient to cover anticipated expenses and capital requirements though 2027.<h2 class="st-heading-2">Optimism For Deramiocel Application</h2>The company is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22. If approved, the company said that its San Diego GMP manufacturing facility will support a potential commercial launch.“Capricor enters 2026 with important regulatory and clinical momentum as we work toward potential approval of Deramiocel for the treatment of Duchenne muscular dystrophy (DMD),” said Linda Marbán, CEO of Capricor.The FDA is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock stayed within ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained about 156% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fly-stock-rallies-on-wall-street-spiking-optimism-after-succesful-alpha-launch/cZdujXtRIaP">FLY Stock Rallies On Wall Street’s Spiking Optimism After Successful Alpha Launch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy

For the fourth quarter, the company reported a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024.

Capricor Therapeutics Q4 Earnings Call Highlights

Capricor Therapeutics (NASDAQ:CAPR) executives used the company's fourth-quarter and full-year 2025 earnings call to outline progress toward a potential U.S. approval of deramiocel for Duchenne...

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CAPR News

CAPRCapricor Therapeutics Inc